65,437 trials
Meningococcal ACWY Disease
Primary: Percentage of Participants With Booster Response in Terms of Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titer Levels at 1 Month After Booster Vaccination…
Avian Influenza · Influenza Immunisation
Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies — 33.6; 33.5; 39.2; 5.5 titer
Multiple Myeloma
Primary: Recommended Dose of Plitidepsin in Combination With Bortezomib and Dexamethasone — 5.0 mg/m^2 of plitidepsin
Acute Myelogenous Leukemia · Acute Lymphoid Leukemia · Juvenile Myelomonocytic Leukemia
Primary: Relapse Rate — 23.5 percentage of participants
Opioid Use · Shoulder Osteoarthritis · Avascular Necrosis
Primary: Post Op Pain — 3.0; 2.0 score on a scale — p=.297
Breast Neoplasms
Primary: Time-to-Event — NA months
Asthma
Primary: Time to First Exacerbation — 340.656; 123.151 Days — p=0.044
Migraine
Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027
Prostate Cancer
Primary: Safety, as Measured by the Number of Patients With at Least One Adverse Event as Assess by NCI Common Terminology Criteria for Adverse Events (CTCAE) vs. 40 When…
Metastatic Castration-resistant Prostate Cancer
Primary: Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only — 7.39; 3.55 Months — p=<0.0001
Glioma
Primary: Progression Free Survival (PFS) — 82 Participants — p=<0.05
Classical Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 87.1 Percentage of Participants — p=<0.0001
Education
Primary: Change in Self-assessed Likert Scale Relating to Confidence in Breaking Bad News at Baseline and Post-intervention. — 1; 0; 1; 0 Participants
Asthma
Primary: Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID. — 0.37; 0.21 mm/wk
Infectious Skin Disease · Bacterial Skin Disease
Primary: Number of Participants With Clinical Response in the Modified Intent-to-Treat (mITT) Population — 75; 59; 9; 19 participants